After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
Circle Pharma and Verismo feature in coveted sessions.
